Αρχική World News Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer World News Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer Από Ogkologos - 19 Δεκεμβρίου, 2025 645 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Introducing our new podcast for researchers 4 Φεβρουαρίου, 2022 New Approach Uses Much Less Tissue to Analyze Tumor Proteins and... 27 Φεβρουαρίου, 2020 News digest – skin cancer deaths, Public Health England plans and... 22 Αυγούστου, 2020 Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life 30 Σεπτεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Biopsia por aspiración con aguja fina (PAAF): Cómo prepararse y qué... ESMO World Congress on Gastrointestinal Cancer 2020 How to Make a Homemade Face Mask from a Folded Scarf—No... BRCA Gene Testing: Risks, Benefits, Costs, and Coverage